

Pablo Martínez-Martín

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7581964/publications.pdf>

Version: 2024-02-01

450
papers

29,590
citations

7568

77
h-index

7518

151
g-index

486
all docs

486
docs citations

486
times ranked

19868
citing authors

#	ARTICLE	IF	CITATIONS
1	Constipation Predicts Cognitive Decline in Parkinson's Disease: Results from the COPPADIS Cohort at 2-Year Follow-up and Comparison with a Control Group. <i>Journal of Parkinson's Disease</i> , 2022, 12, 315-331.	2.8	10
2	The New Satisfaction with Life and Treatment Scale (SLTS-7) in Patients with Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2022, 12, 453-464.	2.8	6
3	A Patient-Centered Conceptual Model of Symptoms and Their Impact in Early Parkinson's Disease: A Qualitative Study. <i>Journal of Parkinson's Disease</i> , 2022, 12, 137-151.	2.8	10
4	Does the 5-2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5-2-1-positive patients in 7 countries. <i>BMC Neurology</i> , 2022, 22, 35.	1.8	12
5	Impact of age at onset on symptom profiles, treatment characteristics and health-related quality of life in Parkinson's disease. <i>Scientific Reports</i> , 2022, 12, 526.	3.3	18
6	Increased homocysteine levels correlate with cortical structural damage in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2022, 434, 120148.	0.6	13
7	Validation of the Arabic Version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale. <i>Movement Disorders</i> , 2022, 37, 826-841.	3.9	2
8	Validation of the Thai Version of the Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale. <i>Journal of Movement Disorders</i> , 2022, 15, 151-155.	1.3	4
9	Parkinson's Disease Motor Subtypes Change with the Progression of the Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up. <i>Journal of Parkinson's Disease</i> , 2022, 12, 935-955.	2.8	3
10	MNCD: A New Tool for Classifying Parkinson's Disease in Daily Clinical Practice. <i>Diagnostics</i> , 2022, 12, 55.	2.6	3
11	Gender gap in deep brain stimulation for Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2022, 8, 47.	5.3	22
12	Motor Fluctuations Development Is Associated with Non-Motor Symptoms Burden Progression in Parkinson's Disease Patients: A 2-Year Follow-Up Study. <i>Diagnostics</i> , 2022, 12, 1147.	2.6	5
13	Sleep Problems Are Related to a Worse Quality of Life and a Greater Non-Motor Symptoms Burden in Parkinson's Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2021, 34, 642-658.	2.3	15
14	Assessment of Ataxia Rating Scales and Cerebellar Functional Tests: Critique and Recommendations. <i>Movement Disorders</i> , 2021, 36, 283-297.	3.9	52
15	Prevalence of Non-Motor Symptoms and Non-Motor Fluctuations in Parkinson's Disease Using the MDS-NMS. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 231-239.	1.5	35
16	Clinical Non-Motor Phenotyping of Black and Asian Minority Ethnic Compared to White Individuals with Parkinson's Disease Living in the United Kingdom. <i>Journal of Parkinson's Disease</i> , 2021, 11, 299-307.	2.8	15
17	Toward eScales: Digital Administration of the International Parkinson and Movement Disorder Society Rating Scales. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 208-214.	1.5	5
18	Subthalamic Stimulation Improves Quality of Sleep in Parkinson Disease: A 36-Month Controlled Study. <i>Journal of Parkinson's Disease</i> , 2021, 11, 323-335.	2.8	21

#	ARTICLE	IF	CITATIONS
19	The Non-Motor Symptoms Scale in Parkinson's disease: Validation and use. <i>Acta Neurologica Scandinavica</i> , 2021, 143, 3-12.	2.1	49
20	Clinimetrics of the Freezing of Gait Questionnaire for Parkinson Disease During the "off" State. <i>Basic and Clinical Neuroscience</i> , 2021, 12, 69-78.	0.6	0
21	Quality of Life of Older People with Dementia. <i>International Handbooks of Quality-of-life</i> , 2021, , 135-146.	0.5	0
22	Nonmotor symptom burden grading as predictor of cognitive impairment in Parkinson's disease. <i>Brain and Behavior</i> , 2021, 11, e02086.	2.2	6
23	Falls Predict Acute Hospitalization in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021, , 1-20.	2.8	5
24	Cost-Effectiveness of Device-Aided Therapies in Parkinson's Disease: A Structured Review. <i>Journal of Parkinson's Disease</i> , 2021, 11, 475-489.	2.8	11
25	Cross-sectional analysis of the Parkinson's disease Non-motor International Longitudinal Study baseline non-motor characteristics, geographical distribution and impact on quality of life. <i>Scientific Reports</i> , 2021, 11, 9611.	3.3	21
26	Staging Parkinson's Disease Combining Motor and Nonmotor Symptoms Correlates with Disability and Quality of Life. <i>Parkinson's Disease</i> , 2021, 2021, 1-16.	1.1	10
27	Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 48.	5.3	23
28	Predictors of Global Non-Motor Symptoms Burden Progression in Parkinson's Disease. Results from the COPPADIS Cohort at 2-Year Follow-Up. <i>Journal of Personalized Medicine</i> , 2021, 11, 626.	2.5	10
29	In vivo cholinergic basal forebrain degeneration and cognition in Parkinson's disease: Imaging results from the COPPADIS study. <i>Parkinsonism and Related Disorders</i> , 2021, 88, 68-75.	2.2	16
30	Personalised Advanced Therapies in Parkinson's Disease: The Role of Non-Motor Symptoms Profile. <i>Journal of Personalized Medicine</i> , 2021, 11, 773.	2.5	20
31	Predictors of short-term impulsive and compulsive behaviour after subthalamic stimulation in Parkinson disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1313-1318.	1.9	12
32	Effects of safinamide on pain in patients with fluctuating Parkinson's disease. <i>Brain and Behavior</i> , 2021, 11, e2336.	2.2	18
33	Psychometric features of brief pain inventory for Parkinson's disease during medication states. <i>Disability and Rehabilitation</i> , 2021, , 1-6.	1.8	0
34	Predictors of Loss of Functional Independence in Parkinson's Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up and Comparison with a Control Group. <i>Diagnostics</i> , 2021, 11, 1801.	2.6	9
35	In Support of Electronic Versions of Movement Disorder Society Rating Scales. <i>Movement Disorders</i> , 2021, 36, 270-271.	3.9	2
36	Clinimetrics of the Freezing of Gait Questionnaire for Parkinson Disease During the "off" State. <i>Basic and Clinical Neuroscience</i> , 2021, 12, 69-78.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Prevalence of Advanced Parkinson's Disease in Patients Treated in the Hospitals of the Spanish National Healthcare System: The PARADISE Study. <i>Brain Sciences</i> , 2021, 11, 1557.	2.3	3
38	Patient and caregiver outcomes with levodopa-carbidopa intestinal gel in advanced Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 108.	5.3	8
39	Predictors of clinically significant quality of life impairment in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 118.	5.3	17
40	Diplopia Is Frequent and Associated with Motor and Non-Motor Severity in Parkinson's Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up. <i>Diagnostics</i> , 2021, 11, 2380.	2.6	2
41	Identifying Parkinson's disease subtypes with motor and non-motor symptoms via model-based multi-partition clustering. <i>Scientific Reports</i> , 2021, 11, 23645.	3.3	11
42	Identifying comorbidities and lifestyle factors contributing to the cognitive profile of early Parkinson's disease. <i>BMC Neurology</i> , 2021, 21, 477.	1.8	7
43	The Movement Disorder Society Nonmotor Rating Scale: Initial Validation Study. <i>Movement Disorders</i> , 2020, 35, 116-133.	3.9	59
44	Barthel Index and modified Rankin Scale: Psychometric properties during medication phases in idiopathic Parkinson disease. <i>Annals of Physical and Rehabilitation Medicine</i> , 2020, 63, 500-504.	2.3	24
45	Which Scale Best Detects Treatment Response of Tremor in Parkinsonism?. <i>Journal of Parkinson's Disease</i> , 2020, 10, 275-282.	2.8	3
46	Beneficial nonmotor effects of subthalamic and pallidal neurostimulation in Parkinson's disease. <i>Brain Stimulation</i> , 2020, 13, 1697-1705.	1.6	36
47	Non-motor symptom burden in patients with Parkinson's disease with impulse control disorders and compulsive behaviours: results from the COPPADIS cohort. <i>Scientific Reports</i> , 2020, 10, 16893.	3.3	6
48	Effects of Motor Symptom Laterality on Clinical Manifestations and Quality of Life in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1611-1620.	2.8	15
49	Embarrassment and Shame in People With Parkinson's Disease: A New Tool for Self-Assessment. <i>Frontiers in Neurology</i> , 2020, 11, 779.	2.4	1
50	Clinical Characterization of Parkinson's Disease Patients With Cognitive Impairment. <i>Frontiers in Neurology</i> , 2020, 11, 731.	2.4	11
51	Quality of life and non-motor symptoms in Parkinson's disease patients with subthreshold depression. <i>Journal of the Neurological Sciences</i> , 2020, 418, 117109.	0.6	11
52	Interpretation of health-related quality of life outcomes in Parkinson's disease from the EARLYSTIM Study. <i>PLoS ONE</i> , 2020, 15, e0237498.	2.5	5
53	A prospective, controlled study of non-motor effects of subthalamic stimulation in Parkinson's disease: results at the 36-month follow-up. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 687-694.	1.9	36
54	Tolerability of non-ergot oral and transdermal dopamine agonists in younger and older Parkinson's disease patients: an European multicentre survey. <i>Journal of Neural Transmission</i> , 2020, 127, 875-879.	2.8	10

#	ARTICLE	IF	CITATIONS
55	Non-motor symptom burden is strongly correlated to motor complications in patients with Parkinson's disease. <i>European Journal of Neurology</i> , 2020, 27, 1210-1223.	3.3	40
56	Beneficial effect of 24-month bilateral subthalamic stimulation on quality of sleep in Parkinson's disease. <i>Journal of Neurology</i> , 2020, 267, 1830-1841.	3.6	17
57	A Spanish Consensus on the Use of Safinamide for Parkinson's Disease in Clinical Practice. <i>Brain Sciences</i> , 2020, 10, 176.	2.3	7
58	Factor Analysis and Clustering of the Movement Disorder Society's "Non-Motor Rating Scale. <i>Movement Disorders</i> , 2020, 35, 969-975.	3.9	9
59	Drooling in Parkinson's Disease: Prevalence and Progression from the Non-motor International Longitudinal Study. <i>Dysphagia</i> , 2020, 35, 955-961.	1.8	51
60	Impulse control and related behaviors in Parkinson's disease with dementia. <i>European Journal of Neurology</i> , 2020, 27, 944-950.	3.3	15
61	Dementia in long-term Parkinson's disease patients: a multicentre retrospective study. <i>Npj Parkinson's Disease</i> , 2020, 6, 2.	5.3	32
62	Evaluation of the metric properties of the WHODAS 2.0, WHODAS-S, and RADS in the assessment of disability in Parkinsonian patients. <i>Clinical Neurology and Neurosurgery</i> , 2020, 194, 105872.	1.4	9
63	The impact of freezing of gait on functional dependency in Parkinson's disease with regard to motor phenotype. <i>Neurological Sciences</i> , 2020, 41, 2883-2892.	1.9	13
64	Identifying and responding to fatigue and apathy in Parkinson's disease: a review of current practice. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 477-495.	2.8	29
65	Serum Uric Acid Levels and Non-Motor Symptoms in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1003-1010.	2.8	17
66	Discussing sexuality with Parkinson's disease patients: a multinational survey among neurologists. <i>Journal of Neural Transmission</i> , 2019, 126, 1273-1280.	2.8	11
67	Features and impact of missing values in the association of self-rated health with mortality in care homes: a longitudinal study. <i>Health and Quality of Life Outcomes</i> , 2019, 17, 111.	2.4	1
68	Non-motor symptoms burden, mood, and gait problems are the most significant factors contributing to a poor quality of life in non-demented Parkinson's disease patients: Results from the COPPADIS Study Cohort. <i>Parkinsonism and Related Disorders</i> , 2019, 66, 151-157.	2.2	71
69	High ultrasensitive serum C-reactive protein may be related to freezing of gait in Parkinson's disease patients. <i>Journal of Neural Transmission</i> , 2019, 126, 1599-1608.	2.8	11
70	Validation of a self-completed Dystonia Non-Motor Symptoms Questionnaire. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 2054-2065.	3.7	20
71	Restless legs syndrome - the under-recognised non-motor burden: a questionnaire-based cohort study. <i>Postgraduate Medicine</i> , 2019, 131, 473-478.	2.0	6
72	The Parkinson's Disease Composite Scale Is Adequately Responsive to Acute Levodopa Challenge. <i>Parkinson's Disease</i> , 2019, 2019, 1-8.	1.1	5

#	ARTICLE	IF	CITATIONS
73	Non-motor outcomes depend on location of neurostimulation in Parkinson's disease. <i>Brain</i> , 2019, 142, 3592-3604.	7.6	90
74	Pilot Study of the International Parkinson and Movement Disorder Society's sponsored Non-motor Rating Scale (MDS-UOMS). <i>Movement Disorders Clinical Practice</i> , 2019, 6, 227-234.	1.5	31
75	EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 353-365.	3.9	126
76	Validation study of the Parkinson's Fatigue Scale in advanced Parkinson's disease. <i>Patient Related Outcome Measures</i> , 2019, Volume 10, 141-152.	1.2	6
77	Remote Monitoring of Treatment Response in Parkinson's Disease: The Habit of Typing on a Computer. <i>Movement Disorders</i> , 2019, 34, 1488-1495.	3.9	31
78	Scales to assess impulsive and compulsive behaviors in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2019, 34, 791-798.	3.9	49
79	COPPADIS 2015 Cohort of Patients with Parkinson's Disease in Tj ETQq1 1 0.784314 rgBT 1000 subjects included. Results from the baseline evaluation. <i>European Journal of Neurology</i> , 2019, 26, 1399-1407.	3.3	32
80	Psychometric Properties of the Apathy Scale in Advanced Parkinson's Disease. <i>Parkinson's Disease</i> , 2019, 2019, 1-8.	1.1	5
81	Exploring hyperhidrosis and related thermoregulatory symptoms as a possible clinical identifier for the dysautonomic subtype of Parkinson's disease. <i>Journal of Neurology</i> , 2019, 266, 1736-1742.	3.6	27
82	Extensive validation study of the Parkinson's Disease Composite Scale. <i>European Journal of Neurology</i> , 2019, 26, 1281-1288.	3.3	8
83	The Parkinson's disease e-diary: Developing a clinical and research tool for the digital age. <i>Movement Disorders</i> , 2019, 34, 676-681.	3.9	43
84	Facility ownership and mortality among older adults residing in care homes. <i>PLoS ONE</i> , 2019, 14, e0197789.	2.5	11
85	The Parkinson's Disease Sleep Scale-2 (PDSS-2): Validation of the Spanish Version and Its Relationship With a Roommate-Based Version. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 294-301.	1.5	11
86	Influencing factors when living with Parkinson's disease: A cross-sectional study. <i>Journal of Clinical Nursing</i> , 2019, 28, 3168-3176.	3.0	25
87	Slave to the rhythm: Seasonal differences in non-motor symptoms in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 63, 73-76.	2.2	14
88	Applications of the European Parkinson's Disease Association sponsored Parkinson's Disease Composite Scale (PDCS). <i>Npj Parkinson's Disease</i> , 2019, 5, 26.	5.3	6
89	The long-term direct and indirect economic burden among Parkinson's disease caregivers in the United States. <i>Movement Disorders</i> , 2019, 34, 236-245.	3.9	56
90	Validation of the self-administered version of the international Restless Legs Syndrome study group severity rating scale - The sIRLS. <i>Sleep Medicine</i> , 2019, 54, 94-100.	1.6	34

#	ARTICLE	IF	CITATIONS
91	Reliability and Validity of Fall Efficacy Scale-International in People with Parkinson's Disease during On- and Off-Drug Phases. <i>Parkinson's Disease</i> , 2019, 2019, 1-7.	1.1	20
92	Relationship of Nocturnal Sleep Dysfunction and Pain Subtypes in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 57-64.	1.5	17
93	Evaluation of nocturnal hypokinesia in Parkinson's disease using a novel patient/proxy questionnaire and correlations with objective monitoring. <i>Parkinsonism and Related Disorders</i> , 2019, 61, 219-223.	2.2	10
94	Ultrabilitation: beyond recovery-oriented rehabilitation. <i>Disability and Rehabilitation</i> , 2019, 41, 740-745.	1.8	17
95	The Association Between Balance, Fear of Falling and Daily Activities in Drug Phases and Different Levels of Disease Severity in Patients With Parkinson's Disease. <i>Basic and Clinical Neuroscience</i> , 2019, 10, 355-362.	0.6	11
96	Nonmotor symptoms evolution during 24 months of bilateral subthalamic stimulation in Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 421-430.	3.9	69
97	Independent and Complementary Validation of the QUIP-RS in Advanced Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 341-342.	1.5	3
98	Reply: MoCA for cognitive screening in Parkinson's disease: Beware of floor effect. <i>Movement Disorders</i> , 2018, 33, 499-500.	3.9	2
99	Pain in Parkinson's disease: facts and uncertainties. <i>European Journal of Neurology</i> , 2018, 25, 917.	3.3	66
100	Short-term quality of life after subthalamic stimulation depends on non-motor symptoms in Parkinson's disease. <i>Brain Stimulation</i> , 2018, 11, 867-874.	1.6	36
101	Rating Scales and Performance-based Measures for Assessment of Functional Ability in Huntington's Disease: Critique and Recommendations. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 361-372.	1.5	22
102	Minimal Clinically Important Difference for UPDRS-III in Daily Practice. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 448-450.	1.5	25
103	Quality of Life in Huntington's Disease: Critique and Recommendations for Measures Assessing Patient Health-Related Quality of Life and Caregiver Quality of Life. <i>Movement Disorders</i> , 2018, 33, 742-749.	3.9	23
104	Rating scales for cognition in Huntington's disease: Critique and recommendations. <i>Movement Disorders</i> , 2018, 33, 187-195.	3.9	38
105	Subthalamic Stimulation Improves Quality of Life of Patients Aged 61 Years or Older With Short Duration of Parkinson's Disease. <i>Neuromodulation</i> , 2018, 21, 532-540.	0.8	26
106	Validation study of the hoehn and yahr scale included in the MDS-UPDRS. <i>Movement Disorders</i> , 2018, 33, 651-652.	3.9	32
107	Clinical Rating Scales for Urinary Symptoms in Parkinson Disease: Critique and Recommendations. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 479-491.	1.5	18
108	Relationship between the MDS-UPDRS and Quality of Life: A large multicenter study of 3206 patients. <i>Parkinsonism and Related Disorders</i> , 2018, 52, 83-89.	2.2	46

#	ARTICLE	IF	CITATIONS
109	Improvement of impulse control disorders associated with levodopa+carbidopa intestinal gel treatment in advanced Parkinson's disease. <i>Journal of Neurology</i> , 2018, 265, 1279-1287.	3.6	19
110	Non-motor outcomes of subthalamic stimulation in Parkinson's disease depend on location of active contacts. <i>Brain Stimulation</i> , 2018, 11, 904-912.	1.6	53
111	The Neuropsychiatric Fluctuations Scale for Parkinson's Disease: A Pilot Study. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 265-272.	1.5	11
112	Short-term association between road traffic noise and healthcare demand generated by Parkinson's disease in Madrid, Spain. <i>Gaceta Sanitaria</i> , 2018, 32, 553-558.	1.5	7
113	Comprehensive grading of Parkinson's disease using motor and non-motor assessments: addressing a key unmet need. <i>Expert Review of Neurotherapeutics</i> , 2018, 18, 41-50.	2.8	30
114	Global scales for cognitive screening in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2018, 33, 208-218.	3.9	138
115	Rating Scales for Motor Symptoms and Signs in Huntington's Disease: Critique and Recommendations. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 111-117.	1.5	27
116	The Parkinson's Disease Composite Scale: results of the first validation study. <i>European Journal of Neurology</i> , 2018, 25, 503-511.	3.3	18
117	Quality of life outcome after subthalamic stimulation in Parkinson's disease depends on age. <i>Movement Disorders</i> , 2018, 33, 99-107.	3.9	39
118	Dietary Variations in a Multiethnic Parkinson's Disease Cohort and Possible Influences on Nonmotor Aspects: A Cross-Sectional Multicentre Study. <i>Parkinson's Disease</i> , 2018, 2018, 1-9.	1.1	4
119	Psychometric properties of the Berg balance scale in idiopathic Parkinson's disease in the drug off-phase. <i>Neurological Sciences</i> , 2018, 39, 2175-2181.	1.9	13
120	Reply: Hoehn and Yahr stage 3 and Postural stability item in the Movement Disorder Society's Unified Parkinson's Disease Rating Scale. <i>Movement Disorders</i> , 2018, 33, 1189-1190.	3.9	0
121	First comprehensive tool for screening pain in Parkinson's disease: the King's Parkinson's Disease Pain Questionnaire. <i>European Journal of Neurology</i> , 2018, 25, 1255-1261.	3.3	25
122	Validation of a simple screening tool for early diagnosis of advanced Parkinson's disease in daily practice: the CDEPA questionnaire. <i>Npj Parkinson's Disease</i> , 2018, 4, 20.	5.3	19
123	A Review of Scales to Evaluate Sleep Disturbances in Movement Disorders. <i>Frontiers in Neurology</i> , 2018, 9, 369.	2.4	48
124	Rating Scales for Movement Disorders With Sleep Disturbances: A Narrative Review. <i>Frontiers in Neurology</i> , 2018, 9, 435.	2.4	7
125	A detailed clinical study of pain in 1957 participants with early/moderate Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 27-32.	2.2	77
126	Reprint of "Neuropsychiatric symptoms, behavioural disorders, and quality of life in Parkinson's disease". <i>Journal of the Neurological Sciences</i> , 2017, 374, 3-8.	0.6	26

#	ARTICLE	IF	CITATIONS
127	Systematic review of severity scales and screening instruments for tics: Critique and recommendations. <i>Movement Disorders</i> , 2017, 32, 467-473.	3.9	92
128	Differences in <scp>MDS</scp>â€œ<scp>UPDRS</scp> Scores Based on Hoehn and Yahr Stage and Disease Duration. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 536-544.	1.5	65
129	Quality of Life of Community-Dwelling Older Adults in Spain. <i>Community Quality-of-life and Well-being</i> , 2017, , 269-286.	0.2	1
130	Response to letter by Saenzâ€œFarret et al. on â€œRating scales for behavioral symptoms in Huntington's disease: Critique and recommendationsâ€œ. <i>Movement Disorders</i> , 2017, 32, 482-482.	3.9	0
131	A protective personal factor against disability and dependence in the elderly: an ordinal regression analysis with nine geographically-defined samples from Spain. <i>BMC Geriatrics</i> , 2017, 17, 42.	2.7	9
132	Distribution and impact on quality of life of the pain modalities assessed by the Kingâ€™s Parkinsonâ€™s disease pain scale. <i>Npj Parkinson's Disease</i> , 2017, 3, 8.	5.3	27
133	What is quality of life and how do we measure it? Relevance to Parkinson's disease and movement disorders. <i>Movement Disorders</i> , 2017, 32, 382-392.	3.9	73
134	Clinical Determinants of Parkinson's Diseaseâ€œassociated Pain Using the King's Parkinson's Disease Pain Scale. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 545-551.	1.5	27
135	Neuropsychiatric symptoms, behavioural disorders, and quality of life in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2017, 373, 173-178.	0.6	93
136	Non-Motor Symptoms Assessed by Non-Motor Symptoms Questionnaire and Non-Motor Symptoms Scale in Parkinson's Disease in Selected Asian Populations. <i>Neuroepidemiology</i> , 2017, 49, 1-17.	2.3	29
137	Falling upward with Parkinsonâ€™s disease. <i>Npj Parkinson's Disease</i> , 2017, 3, 29.	5.3	4
138	Measurement of Nonmotor Symptoms in Clinical Practice. <i>International Review of Neurobiology</i> , 2017, 133, 291-345.	2.0	18
139	Clinical rating scale for pantothenate kinaseâ€œassociated neurodegeneration: A pilot study. <i>Movement Disorders</i> , 2017, 32, 1620-1630.	3.9	18
140	Clinical Assessments in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 132, 129-182.	2.0	63
141	Advanced Parkinsonâ€™s or â€œcomplex phaseâ€œParkinsonâ€™s disease? Re-evaluation is needed. <i>Journal of Neural Transmission</i> , 2017, 124, 1529-1537.	2.8	46
142	Structural correlates of apathy in Alzheimer's disease: a multimodal MRI study. <i>International Journal of Geriatric Psychiatry</i> , 2017, 32, 922-930.	2.7	27
143	Selfâ€œAssessment of Disability in Parkinson's Disease: The <scp>MDS</scp>â€œ<scp>UPDRS</scp> Part <scp>II</scp> Versus Clinicianâ€œBased Ratings. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 529-535.	1.5	14
144	Non motor symptoms in progressive supranuclear palsy: prevalence and severity. <i>Npj Parkinson's Disease</i> , 2017, 3, 35.	5.3	29

#	ARTICLE	IF	CITATIONS
145	A Consensus Set of Outcomes for Parkinson's Disease from the International Consortium for Health Outcomes Measurement. <i>Journal of Parkinson's Disease</i> , 2017, 7, 533-543.	2.8	45
146	Cross-Fertilization of Studies in Neurodegeneration. , 2017, 07, .		0
147	Parkinson's Disease Subtypes Identified from Cluster Analysis of Motor and Non-motor Symptoms. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 301.	3.4	94
148	Parkinson's Disease Severity at 3 Years Can Be Predicted from Non-Motor Symptoms at Baseline. <i>Frontiers in Neurology</i> , 2017, 8, 551.	2.4	19
149	Consensus on the Definition of Advanced Parkinson's Disease: A Neurologists-Based Delphi Study (CEPA Study). <i>Parkinson's Disease</i> , 2017, 2017, 1-8.	1.1	53
150	Quality of Life in Parkinson's Disease. , 2017, , 165-180.		0
151	Rating Scales in Movement Disorders. , 2017, , 65-75.		4
152	Drivers: A Biologically Contextualized, Cross-Inferential View of the Epidemiology of Neurodegenerative Disorders. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 1003-1022.	2.6	8
153	Etiologic Framework for the Study of Neurodegenerative Disorders as Well as Vascular and Metabolic Comorbidities on the Grounds of Shared Epidemiologic and Biologic Features. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 138.	3.4	6
154	Non-Motor Symptoms in Patients Suffering from Motor Neuron Diseases. <i>Frontiers in Neurology</i> , 2016, 7, 117.	2.4	43
155	Rating scales for behavioral symptoms in Huntington's disease: Critique and recommendations. <i>Movement Disorders</i> , 2016, 31, 1466-1478.	3.9	44
156	Disability Rating Scales in Parkinson's Disease: Critique and Recommendations. <i>Movement Disorders</i> , 2016, 31, 1455-1465.	3.9	87
157	Measurement instruments to assess posture, gait, and balance in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2016, 31, 1342-1355.	3.9	212
158	Modeling anxiety in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 310-316.	3.9	17
159	A European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists. <i>European Journal of Neurology</i> , 2016, 23, 1255-1261.	3.3	76
160	Improvement of dyskinesias with L-DOPA infusion in advanced Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2016, 133, 451-458.	2.1	23
161	Night-time sleep in Parkinson's disease – the potential use of Parkinson's KinetiGraph: a prospective comparative study. <i>European Journal of Neurology</i> , 2016, 23, 1275-1288.	3.3	38
162	Associations between chronic conditions, body functions, activity limitations and participation restrictions: a cross-sectional approach in Spanish non-clinical populations. <i>BMJ Open</i> , 2016, 6, e010446.	1.9	16

#	ARTICLE	IF	CITATIONS
163	Analysis of four scales for global severity evaluation in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2016, 2, 16007.	5.3	27
164	Assessing health-related quality of life with the SCOPA-PS in French individuals with Parkinson's disease having undergone DBS-STN: A validation study. <i>Revue Neurologique</i> , 2016, 172, 281-288.	1.5	2
165	Quality of life of institutionalized older adults by dementia severity. <i>International Psychogeriatrics</i> , 2016, 28, 83-92.	1.0	17
166	Rating of daytime and nighttime symptoms in RLS: validation of the RLS-6 scale of restless legs syndrome/Willis-Ekbom disease. <i>Sleep Medicine</i> , 2016, 20, 116-122.	1.6	29
167	Postural instability and gait are associated with severity and prognosis of Parkinson disease. <i>Neurology</i> , 2016, 86, 2243-2250.	1.1	78
168	Rating Scales for Pain in Parkinson's Disease: Critique and Recommendations. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 527-537.	1.5	46
169	Validation of the Kohnen Restless Legs Syndrome Quality of Life instrument. <i>Sleep Medicine</i> , 2016, 24, 10-17.	1.6	12
170	The hidden sister of motor fluctuations in Parkinson's disease: A review on nonmotor fluctuations. <i>Movement Disorders</i> , 2016, 31, 1080-1094.	3.9	112
171	Beyond patient-centered care: person-centered care for Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2016, 2, 16019.	5.3	12
172	Living with chronic illness scale: international validation of a new self-report measure in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2016, 2, 16022.	5.3	14
173	COPPADIS-2015 (COhort of Patients with PArkinson's Disease in Spain, 2015), a global clinical evaluations, serum biomarkers, genetic studies and neuroimaging prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression. <i>BMC Neurology</i> , 2016, 16, 26.	1.8	66
174	Self-perceived health status, gender, and work status. <i>Journal of Women and Aging</i> , 2016, 28, 386-394.	1.0	16
175	Accuracy of screening instruments for detection of neuropsychiatric syndromes in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 270-279.	3.9	55
176	Effect of heat waves on morbidity and mortality due to Parkinson's disease in Madrid: A time-series analysis. <i>Environment International</i> , 2016, 89-90, 1-6.	10.0	37
177	Evaluation of severity of predominantly non-dopaminergic symptoms in Parkinson's disease: The SENS-PD scale. <i>Parkinsonism and Related Disorders</i> , 2016, 25, 39-44.	2.2	16
178	Satisfaction with Life Scale (SLS-6): First validation study in Parkinson's disease population. <i>Parkinsonism and Related Disorders</i> , 2016, 25, 52-57.	2.2	18
179	Beneficial Effects of Bilateral Subthalamic Stimulation on Non-Motor Symptoms in Parkinson's Disease. <i>Brain Stimulation</i> , 2016, 9, 78-85.	1.6	86
180	Residential Environment and Health Conditions Among Older-Adults in Community-Dwelling in Spain: What Influences Quality of Life?. <i>International Perspectives on Aging</i> , 2016, , 149-174.	0.4	8

#	ARTICLE	IF	CITATIONS
181	Measuring the Burden of Hospitalization in Patients with Parkinson's Disease in Spain. PLoS ONE, 2016, 11, e0151563.	2.5	24
182	Validation of the QUEST for German-speaking countries. International Journal of Neuroscience, 2016, 126, 127-34.	1.6	2
183	Non-motor symptoms burden in treated and untreated early Parkinson's disease patients: argument for non-motor subtypes. European Journal of Neurology, 2015, 22, 1145-1150.	3.3	64
184	A review of "Validity and Validation in Social, Behavioral, and Health Sciences", Bruno D. Zumbo and Eric K.H. Chan Editors. Applied Research in Quality of Life, 2015, 10, 547-549.	2.4	0
185	King's Parkinson's disease pain scale, the first scale for pain in PD: An international validation. Movement Disorders, 2015, 30, 1623-1631.	3.9	189
186	A Pilot Prospective, Multicenter Observational Study of Dopamine Agonist Withdrawal Syndrome in Parkinson's Disease. Movement Disorders Clinical Practice, 2015, 2, 170-174.	1.5	19
187	Scales to Assess Clinical Features of Progressive Supranuclear Palsy: MDS Task Force Report. Movement Disorders Clinical Practice, 2015, 2, 127-134.	1.5	20
188	Proposing a Parkinson's disease-specific tremor scale from the MDS-UPDRS. Movement Disorders, 2015, 30, 1139-1143.	3.9	14
189	Social robots in advanced dementia. Frontiers in Aging Neuroscience, 2015, 7, 133.	3.4	142
190	The Vallecas Project: A Cohort to Identify Early Markers and Mechanisms of Alzheimer's Disease. Frontiers in Aging Neuroscience, 2015, 7, 181.	3.4	28
191	Parkinson Symptoms and Health Related Quality of Life as Predictors of Costs: A Longitudinal Observational Study with Linear Mixed Model Analysis. PLoS ONE, 2015, 10, e0145310.	2.5	35
192	Euro-IMPACT: A Multicenter Comparative Observational Study of Dopamine Agonist Withdrawal and Levodopa Infusion in Parkinson's Disease. Movement Disorders, 2015, 30, 510-516.	3.9	203
193	Assessing the non-motor symptoms of Parkinson's disease: MDS-UPDRS and NMS Scale. European Journal of Neurology, 2015, 22, 37-43.	3.3	82
194	Factor analysis of the Hamilton Depression Rating Scale in Parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 142-146.	2.2	45
195	Is the Parkinson anxiety scale comparable across raters?. Movement Disorders, 2015, 30, 545-551.	3.9	7
196	Nonmotor predictors for levodopa requirement in de novo patients with Parkinson's disease. Movement Disorders, 2015, 30, 373-378.	3.9	41
197	Active ageing and quality of life: factors associated with participation in leisure activities among institutionalized older adults, with and without dementia. Aging and Mental Health, 2015, 19, 1031-1041.	2.8	105
198	Effect of anticholinergic drugs on cognitive impairment in the elderly. Revista De Psiquiatria Y Salud Mental (English Edition), 2015, 8, 35-43.	0.3	8

#	ARTICLE	IF	CITATIONS
199	Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1133-1144.	2.2	156
200	The burden of non-motor symptoms in Parkinson's disease using a self-completed non-motor questionnaire: A simple grading system. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 287-291.	2.2	93
201	Curcumin/Melatonin Hybrid 5-(4-Hydroxy-phenyl)-3-oxo-pentanoic Acid [2-(5-Methoxy-1 <i>H</i> -indol-3-yl)-ethyl]-amide Ameliorates AD-Like Pathology in the APP/PS1 Mouse Model. <i>ACS Chemical Neuroscience</i> , 2015, 6, 1393-1399.	3.5	51
202	Validation of the multimodal assessment of capacities in severe dementia: a novel cognitive and functional scale for use in severe dementia. <i>Journal of Neurology</i> , 2015, 262, 1198-1208.	3.6	8
203	Impact of Pharmacotherapy on Quality of Life in Patients with Parkinson's Disease. <i>CNS Drugs</i> , 2015, 29, 397-413.	5.9	35
204	Neuropsychiatric symptoms and caregiver's burden in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 629-634.	2.2	166
205	International validation of a behavioral scale in Parkinson's disease without dementia. <i>Movement Disorders</i> , 2015, 30, 705-713.	3.9	88
206	Prolonged-release oxycodone/naloxone for treatment of severe pain in patients with Parkinson's disease (PANDA): a double-blind, randomised, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2015, 14, 1161-1170.	10.2	102
207	Estimating the direct and indirect costs associated with Parkinson's disease. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 889-911.	1.4	56
208	Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease – Clinical practice recommendations. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1023-1030.	2.2	126
209	Quality of life by proxy and mortality in institutionalized older adults with dementia. <i>Geriatrics and Gerontology International</i> , 2015, 15, 38-44.	1.5	15
210	Quality of life across three groups of older adults differing in cognitive status and place of residence. <i>Geriatrics and Gerontology International</i> , 2015, 15, 627-635.	1.5	26
211	Quantitative assessment of non-motor fluctuations in Parkinson's disease using the Non-Motor Symptoms Scale (NMSS). <i>Journal of Neural Transmission</i> , 2015, 122, 1673-1684.	2.8	52
212	Double-blind Randomized Trial of tDCS Versus Sham in Parkinson Patients With Mild Cognitive Impairment Receiving Cognitive Training. <i>Brain Stimulation</i> , 2015, 8, 1223-1225.	1.6	55
213	Parkinson's disease severity levels and MDS-Unified Parkinson's Disease Rating Scale. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 50-54.	2.2	216
214	Associative participation of older adults and subjective quality of life: exploring self-selection bias. <i>Ageing and Society</i> , 2015, 35, 1343-1363.	1.7	8
215	Quality of life in older people with dementia: A multilevel study of individual attributes and residential care center characteristics. <i>Geriatrics and Gerontology International</i> , 2015, 15, 104-110.	1.5	31
216	A Novel Rating Scale for the Measurement of Apathy in Institutionalized Persons with Dementia: The APADEM-NH. <i>American Journal of Geriatric Psychiatry</i> , 2015, 23, 149-159.	1.2	16

#	ARTICLE	IF	CITATIONS
217	Leisure Activities and Quality of Life Among Older Adults in Spain. Social Indicators Research Series, 2015, , 163-189.	0.3	13
218	Comparative Incidence of Conformational, Neurodegenerative Disorders. PLoS ONE, 2015, 10, e0137342.	2.5	21
219	Independent Validation of the SEND-PD and Correlation with the MDS-UPDRS Part IA. Parkinson's Disease, 2014, 2014, 1-5.	1.1	6
220	Non-Motor Symptoms Profile and Burden in Drug Naïve Versus Long-Term Parkinson's Disease Patients. Journal of Parkinson's Disease, 2014, 4, 541-547.	2.8	41
221	PREDICTING THE EQ-5D FROM THE PARKINSON'S DISEASE QUESTIONNAIRE PDQ-8 USING MULTI-DIMENSIONAL BAYESIAN NETWORK CLASSIFIERS. Biomedical Engineering - Applications, Basis and Communications, 2014, 26, 1450015.	0.6	6
222	Nonmotor symptoms and focal cervical dystonia: Observations from 102 patients. Basal Ganglia, 2014, 4, 117-120.	0.3	37
223	What impacts on the stress symptoms of Parkinson's carers? Results from the Parkinson's UK Members' Survey. Disability and Rehabilitation, 2014, 36, 199-204.	1.8	23
224	EQ-5D rated by proxy in institutionalized older adults with dementia: Psychometric pros and cons. Geriatrics and Gerontology International, 2014, 14, 346-353.	1.5	41
225	Nonmotor symptoms and health-related quality of life in early Parkinson's disease. Movement Disorders, 2014, 29, 166-168.	3.9	22
226	Self-perceived health and quality of life by activity status in community-dwelling older adults. Geriatrics and Gerontology International, 2014, 14, 464-473.	1.5	21
227	Multiple sclerosis is associated with high trait anger: A case-control study. Journal of the Neurological Sciences, 2014, 340, 69-74.	0.6	11
228	Factors determining when to start levodopa/carbidopa/entacapone treatment in Spanish patients with Parkinson's disease. Neurología (English Edition), 2014, 29, 153-160.	0.4	0
229	Perceptions of symptoms and expectations of advanced therapy for Parkinson's disease: preliminary report of a Patient-Reported Outcome tool for Advanced Parkinson's disease (PRO-APD). Health and Quality of Life Outcomes, 2014, 12, 11.	2.4	41
230	Rating scales and questionnaires for assessment of sleep disorders in Parkinson's disease: what they inform about?. Journal of Neural Transmission, 2014, 121, 33-40.	2.8	32
231	Relationship between the MDS-UPDRS domains and the health-related quality of life of Parkinson's disease patients. European Journal of Neurology, 2014, 21, 519-524.	3.3	46
232	Anxiety Has Specific Syndromal Profiles in Parkinson Disease: A Data-Driven Approach. American Journal of Geriatric Psychiatry, 2014, 22, 1410-1417.	1.2	32
233	Non-motor symptoms of Parkinson's disease A review from the past. Journal of the Neurological Sciences, 2014, 338, 30-33.	0.6	93
234	Guide to Assessment Scales in Parkinson's Disease. , 2014, , .		5

#	ARTICLE	IF	CITATIONS
235	Importance of nondopaminergic features in evaluating disease severity of Parkinson disease. <i>Neurology</i> , 2014, 82, 412-418.	1.1	36
236	Characterizing motor and non-motor aspects of early-morning off periods in Parkinson's disease: An international multicenter study. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1231-1235.	2.2	76
237	Which factors are associated with mortality in institutionalized older adults with dementia?. <i>Archives of Gerontology and Geriatrics</i> , 2014, 59, 522-527.	3.0	8
238	Measurement of costs and scales for outcome evaluation in health economic studies of Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 169-176.	3.9	15
239	The Parkinson Anxiety Scale (PAS): Development and validation of a new anxiety scale. <i>Movement Disorders</i> , 2014, 29, 1035-1043.	3.9	173
240	Comparison of the clinical profile of Parkinson's disease between Spanish and Cameroonian Cohorts. <i>Journal of the Neurological Sciences</i> , 2014, 336, 122-126.	0.6	20
241	Change and predictors of quality of life in institutionalized older adults with dementia. <i>Quality of Life Research</i> , 2014, 23, 2595-2601.	3.1	27
242	Factores determinantes del inicio de tratamiento con levodopa/carbidopa/entacapona en pacientes espa±oles con enfermedad de Parkinson. <i>NeurologÁa</i> , 2014, 29, 153-160.	0.7	2
243	Review of Quality of Life Instruments for the Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED): Critique and Recommendations. <i>Journal of Clinical Sleep Medicine</i> , 2014, 10, 1351-1357.	2.6	25
244	Motor Effects of Radio Electric Asymmetric Conveyer in Alzheimer's Disease: Results from a Cross-Over Trial. <i>Journal of Alzheimer's Disease</i> , 2014, 42, 325-332.	2.6	17
245	Review of Severity Rating Scales for Restless Legs Syndrome: Critique and Recommendations. <i>Movement Disorders Clinical Practice</i> , 2014, 1, 317-324.	1.5	32
246	Cognition and Neuropsychiatric Symptoms. , 2014, , 67-89.		1
247	Towards an Age-Dependent Transmission Model of Acquired and Sporadic Creutzfeldt-Jakob Disease. <i>PLoS ONE</i> , 2014, 9, e109412.	2.5	10
248	Review of Diagnostic Instruments for the Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED): Critique and Recommendations. <i>Journal of Clinical Sleep Medicine</i> , 2014, 10, 1343-1349.	2.6	47
249	Global Severity Assessments. , 2014, , 25-29.		0
250	Quality of Life Scales. , 2014, , 91-102.		1
251	Multi-domain Scales. , 2014, , 13-23.		2
252	Comprehensive Non-motor Symptoms Assessments. , 2014, , 43-47.		0

#	ARTICLE	IF	CITATIONS
253	Motor Impairment and Disability Scales. , 2014, , 31-42.		1
254	Scales for Measuring Parkinsonism in Demented Patients. , 2014, , 117-128.		0
255	Scales that Evaluate Specific Non-motor Disorders. , 2014, , 49-65.		2
256	Individual's perspective of local community environment and health indicators in older adults. Geriatrics and Gerontology International, 2013, 13, 130-138.	1.5	16
257	Is AD a homogeneous nosologic entity? Yes. Journal of Neural Transmission, 2013, 120, 1467-1473.	2.8	0
258	Dystonia rating scales: Critique and recommendations. Movement Disorders, 2013, 28, 874-883.	3.9	150
259	Daytime apomorphine infusion combined with transdermal Rotigotine patch therapy is tolerated at 2 years: A 24-h treatment option in Parkinson's disease. Basal Ganglia, 2013, 3, 127-130.	0.3	13
260	Perceived Social Support of Older Adults in Spain. Applied Research in Quality of Life, 2013, 8, 183-200.	2.4	16
261	Quality of life (QoL) in community-dwelling and institutionalized Alzheimer's disease (AD) patients. Archives of Gerontology and Geriatrics, 2013, 57, 257-262.	3.0	25
262	Clinical Determinants of Health-related Quality of Life in Mexican Patients with Parkinson's Disease. Archives of Medical Research, 2013, 44, 110-114.	3.3	25
263	Dementia in Parkinson's disease: Usefulness of the pill questionnaire. Movement Disorders, 2013, 28, 1832-1837.	3.9	10
264	Effects of rotigotine transdermal system on non-motor symptoms in Parkinson's disease: an overview. Expert Review of Neurotherapeutics, 2013, 13, 1329-1342.	2.8	5
265	The MDS-UPDRS Part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson's disease. Parkinsonism and Related Disorders, 2013, 19, 889-893.	2.2	55
266	An effective environmental intervention for management of the "mirror sign" in a case of probable Lewy body dementia. Neurocase, 2013, 19, 1-13.	0.6	16
267	Discrimination Analysis of Blood Plasma Associated with Alzheimer's Disease Using Vibrational Spectroscopy. Journal of Alzheimer's Disease, 2013, 34, 911-920.	2.6	57
268	Task force report: Scales for screening and evaluating tremor: Critique and recommendations. Movement Disorders, 2013, 28, 1793-1800.	3.9	124
269	Expanded and independent validation of the Movement Disorder Society's "Unified Parkinson's Disease Rating Scale (MDS-UPDRS). Journal of Neurology, 2013, 260, 228-236.	3.6	169
270	Unveiling relevant non-motor Parkinson's disease severity symptoms using a machine learning approach. Artificial Intelligence in Medicine, 2013, 58, 195-202.	6.5	50

#	ARTICLE	IF	CITATIONS
271	Rasch analysis of anxiety scales in Parkinson's disease. <i>Journal of Psychosomatic Research</i> , 2013, 74, 414-419.	2.6	26
272	Relationship between sleep disorders and other non-motor symptoms in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 1152-1155.	2.2	76
273	Instruments for holistic assessment of Parkinson's disease. <i>Journal of Neural Transmission</i> , 2013, 120, 559-564.	2.8	6
274	Rotigotine and specific non-motor symptoms of Parkinson's disease: Post hoc analysis of RECOVER. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 660-665.	2.2	112
275	Designing a new scale to measure anxiety symptoms in Parkinson's disease: item selection based on canonical correlation analysis. <i>European Journal of Neurology</i> , 2013, 20, 1198-1203.	3.3	17
276	Independent validation of the Non motor Symptoms Scale for Parkinson's disease in Brazilian patients. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 115-119.	2.2	12
277	Burden and health-related quality of life among caregivers of Brazilian Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 943-948.	2.2	64
278	Modeling depression in Parkinson disease. <i>Neurology</i> , 2013, 81, 1036-1043.	1.1	55
279	Motor Effects of REAC in Advanced Alzheimer's Disease: Results From a Pilot Trial. <i>Journal of Alzheimer's Disease</i> , 2013, 36, 297-302.	2.6	21
280	Robotherapy with Dementia Patients. <i>International Journal of Advanced Robotic Systems</i> , 2013, 10, 10.	2.1	36
281	Comorbidity, health status, and quality of life in institutionalized older people with and without dementia. <i>International Psychogeriatrics</i> , 2013, 25, 1077-1084.	1.0	27
282	A Proposal for a Comprehensive Grading of Parkinson's Disease Severity Combining Motor and Non-Motor Assessments: Meeting an Unmet Need. <i>PLoS ONE</i> , 2013, 8, e57221.	2.5	95
283	Exploring Requirements and Alternative Pet Robots for Robot Assisted Therapy with Older Adults with Dementia. <i>Lecture Notes in Computer Science</i> , 2013, , 104-115.	1.3	32
284	CHAPTER 1. Parkinson's Disease: Symptoms, Unmet Needs and New Therapeutic Targets. <i>RSC Drug Discovery Series</i> , 2013, , 3-25.	0.3	1
285	Intrajejunal Levodopa Versus Conventional Therapy in Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2012, 35, 205-207.	0.7	51
286	Genetic variability of the gene cluster CALHM1-3 in sporadic Creutzfeldt-Jakob disease. <i>Prion</i> , 2012, 6, 407-412.	1.8	14
287	Rapidly Progressive Alzheimer's Disease: A Multicenter Update. <i>Journal of Alzheimer's Disease</i> , 2012, 30, 751-756.	2.6	48
288	A Rating Scale for Gait Evaluation in Cognitive Deterioration (RSGE-CD): Validation Study. <i>Journal of Alzheimer's Disease</i> , 2012, 31, 543-553.	2.6	11

#	ARTICLE	IF	CITATIONS
289	Clinical and Anatomical Correlates of Gait Dysfunction in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 33, 495-505.	2.6	31
290	Health-related quality of life as an outcome variable in Parkinson's disease. <i>Therapeutic Advances in Neurological Disorders</i> , 2012, 5, 105-117.	3.5	43
291	Promoting Research in Advanced Dementia: Early Clinical Results of the Alzheimer Center Reina Sofía Foundation. <i>Journal of Alzheimer's Disease</i> , 2012, 28, 211-222.	2.6	14
292	Design, measures and sample characteristics of the CadeViMa-Spain survey on quality of life in community-dwelling older adults. <i>International Psychogeriatrics</i> , 2012, 24, 425-438.	1.0	31
293	Rasch analysis of the International Wellbeing Index in older adults. <i>International Psychogeriatrics</i> , 2012, 24, 324-332.	1.0	17
294	Anxiety and motor fluctuations in Parkinson's disease: A cross-sectional observational study. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 1084-1088.	2.2	79
295	2.135 CHARACTERISING NON MOTOR PATTERNS OF EARLY MORNING OFF PERIODS IN PARKINSON'S DISEASE: AN INTERNATIONAL STUDY. <i>Parkinsonism and Related Disorders</i> , 2012, 18, S110.	2.2	2
296	Gender-related differences in the burden of non-motor symptoms in Parkinson's disease. <i>Journal of Neurology</i> , 2012, 259, 1639-1647.	3.6	211
297	A short Scale for Evaluation of Neuropsychiatric Disorders in Parkinson's Disease: first psychometric approach. <i>Journal of Neurology</i> , 2012, 259, 2299-2308.	3.6	28
298	Components and determinants of quality of life in community-dwelling older adults. <i>European Journal of Ageing</i> , 2012, 9, 255-263.	2.8	36
299	Health status and well-being of older adults living in the community and in residential care settings: Are differences influenced by age?. <i>Ageing and Mental Health</i> , 2012, 16, 884-891.	2.8	41
300	The Q10 questionnaire for detection of wearing-off phenomena in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 382-385.	2.2	29
301	A Common BACE1 Polymorphism Is a Risk Factor for Sporadic Creutzfeldt-Jakob Disease. <i>PLoS ONE</i> , 2012, 7, e43926.	2.5	10
302	Self-perceived health status in older adults: regional and sociodemographic inequalities in Spain. <i>Revista De Saude Publica</i> , 2012, 46, 310-319.	1.7	32
303	Quality of life and burden in caregivers for patients with Parkinson's disease: concepts, assessment and related factors. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2012, 12, 221-230.	1.4	112
304	Improvements in nocturnal symptoms with ropinirole prolonged release in patients with advanced Parkinson's disease. <i>European Journal of Neurology</i> , 2012, 19, 105-113.	3.3	84
305	Infrared spectroscopic analysis of mononuclear leukocytes in peripheral blood from Alzheimer's disease patients. <i>Analytical and Bioanalytical Chemistry</i> , 2012, 402, 2015-2021.	3.7	23
306	How to Evaluate Validation Data. , 2012, , 16-41.		17

#	ARTICLE	IF	CITATIONS
307	Non-motor symptoms in a Flanders-Belgian population of 215 Parkinson's disease patients as assessed by the Non-Motor Symptoms Questionnaire. <i>American Journal of Neurodegenerative Disease</i> , 2012, 1, 160-7.	0.1	24
308	Psychometric properties of the Spanish QoL-AD with institutionalized dementia patients and their family caregivers in Spain. <i>Aging and Mental Health</i> , 2011, 15, 775-783.	2.8	28
309	The importance of non-motor disturbances to quality of life in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2011, 310, 12-16.	0.6	129
310	PMH47 Validity of the Q10 Questionnaire for Diagnosis of Wearing-off Phenomena in Parkinson's Disease: A Q10 Study. <i>Value in Health</i> , 2011, 14, A295.	0.3	0
311	Handbook of Non-Motor Symptoms in Parkinson's Disease. , 2011, , .		6
312	The CAREQOL-MS was a useful instrument to measure caregiver quality of life in multiple sclerosis. <i>Journal of Clinical Epidemiology</i> , 2011, 64, 675-686.	5.0	44
313	Parkinson's disease: The non-motor issues. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 717-723.	2.2	313
314	Dementia associated with Parkinson's disease: Applying the Movement Disorder Society Task Force criteria. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 621-624.	2.2	61
315	An in-Depth Look at the Non Motor Symptom Scale. , 2011, , 37-43.		0
316	Sleep Duration and Time during Different Periods of the Day and Night in Patients with Advanced Parkinson's Disease Receiving Adjunctive Ropinirole Prolonged Release. <i>Parkinson's Disease</i> , 2011, 2011, 1-8.	1.1	7
317	The Possible Clinical Predictors of Fatigue in Parkinson's Disease: A Study of 135 Patients as Part of International Nonmotor Scale Validation Project. <i>Parkinson's Disease</i> , 2011, 2011, 1-7.	1.1	13
318	Genetic Cross-Interaction between APOE and PRNP in Sporadic Alzheimer's and Creutzfeldt-Jakob Diseases. <i>PLoS ONE</i> , 2011, 6, e22090.	2.5	43
319	Psychometric properties of the International Wellbeing Index in community-dwelling older adults. <i>International Psychogeriatrics</i> , 2011, 23, 161-169.	1.0	46
320	GREATER RISK OF ALZHEIMER'S DISEASE IN OLDER ADULTS WITH INSOMNIA. <i>Journal of the American Geriatrics Society</i> , 2011, 59, 559-562.	2.6	139
321	Prevalence and European comparison of dementia in a 75-year-old composite population in Spain. <i>Acta Neurologica Scandinavica</i> , 2011, 123, 316-324.	2.1	25
322	Medical, environmental and personal factors of disability in the elderly in Spain: a screening survey based on the International Classification of Functioning. <i>Gaceta Sanitaria</i> , 2011, 25, 29-38.	1.5	17
323	Residential satisfaction, sense of belonging and loneliness among older adults living in the community and in care facilities. <i>Health and Place</i> , 2011, 17, 1183-1190.	3.3	92
324	Measurement properties of the Community Wellbeing Index in older adults. <i>Quality of Life Research</i> , 2011, 20, 733-743.	3.1	65

#	ARTICLE	IF	CITATIONS
325	Prevalence of disability in a composite 75 year-old population in Spain: A screening survey based on the International Classification of Functioning. BMC Public Health, 2011, 11, 176.	2.9	36
326	Anxiety rating scales in Parkinson's disease: A validation study of the Hamilton anxiety rating scale, the Beck anxiety inventory, and the hospital anxiety and depression scale. Movement Disorders, 2011, 26, 407-415.	3.9	158
327	Clinical subtypes of Parkinson's disease. Movement Disorders, 2011, 26, 51-58.	3.9	186
328	The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Movement Disorders, 2011, 26, 399-406.	3.9	744
329	Parkinson's disease sleep scale validation of the revised version PDSS. Movement Disorders, 2011, 26, 644-652.	3.9	296
330	Symptomatology and markers of anxiety disorders in Parkinson's disease: A cross-sectional study. Movement Disorders, 2011, 26, 484-492.	3.9	142
331	Health-related quality of life scales in Parkinson's disease: Critique and recommendations. Movement Disorders, 2011, 26, 2371-2380.	3.9	234
332	Wearing-off scales in Parkinson's disease: Critique and recommendations. Movement Disorders, 2011, 26, 2169-2175.	3.9	101
333	Caregivers' estimation of patients' quality of life (QoL) in Alzheimer's disease (AD): An approach using the ADRQL. Archives of Gerontology and Geriatrics, 2011, 53, 13-18.	3.0	29
334	Chronic Subcutaneous Infusion Therapy with Apomorphine in Advanced Parkinson's Disease Compared to Conventional Therapy: A Real Life Study of Non Motor Effect. Journal of Parkinson's Disease, 2011, 1, 197-203.	2.8	107
335	Factors Associated With Loneliness of Noninstitutionalized and Institutionalized Older Adults. Journal of Aging and Health, 2011, 23, 177-194.	1.7	174
336	Assessing Non-Motor Symptoms: An Overview of Scales and Questionnaires. , 2011, , 27-35.		0
337	The nondeclaration of nonmotor symptoms of Parkinson's disease to health care professionals: An international study using the nonmotor symptoms questionnaire. Movement Disorders, 2010, 25, 704-709.	3.9	342
338	Psychometric properties of the SCOPA-AUT Brazilian Portuguese version. Movement Disorders, 2010, 25, 205-212.	3.9	23
339	Motor laterality asymmetry and nonmotor symptoms in Parkinson's disease. Movement Disorders, 2010, 25, 70-75.	3.9	79
340	Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease. Movement Disorders, 2010, 25, 805-822.	3.9	193
341	Task force report on scales to assess dyskinesia in Parkinson's disease: Critique and recommendations. Movement Disorders, 2010, 25, 1131-1142.	3.9	90
342	Cross-cultural evaluation of the modified Parkinson Psychosis Rating Scale across disease stages. Movement Disorders, 2010, 25, 1391-1398.	3.9	8

#	ARTICLE	IF	CITATIONS
343	Independent validation of the scales for outcomes in Parkinson's disease's autonomic (SCOPA-AUT). European Journal of Neurology, 2010, 17, 194-201.	3.3	74
344	Should the SCOPA-COG be modified?: a Rasch analysis perspective. European Journal of Neurology, 2010, 17, 202-207.	3.3	13
345	Assessing autonomic symptoms of Parkinson's disease with the SCOPA-AUT: a new perspective from Rasch analysis. European Journal of Neurology, 2010, 17, 273-279.	3.3	31
346	Depression and anxiety in Parkinson disease. Nature Reviews Neurology, 2010, 6, 243-245.	10.1	48
347	Rating Scales in Movement Disorders. , 2010, , 8-16.		1
348	Alzheimer Center Reina Sofia Foundation: Fighting the Disease and Providing Overall Solutions. Journal of Alzheimer's Disease, 2010, 21, 337-348.	2.6	31
349	Efficacy and safety of pallidal stimulation in primary dystonia: results of the Spanish multicentric study. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 65-69.	1.9	67
350	ICF-Based Disability Survey in a Rural Population of Adults and Older Adults Living in Cinco Villas, Northeastern Spain: Design, Methods and Population Characteristics. Neuroepidemiology, 2010, 35, 72-82.	2.3	15
351	Oral and Infusion Levodopa-Based Strategies for Managing Motor Complications in Patients with Parkinson's Disease. CNS Drugs, 2010, 24, 119-129.	5.9	60
352	Composite rating scales. Journal of the Neurological Sciences, 2010, 289, 7-11.	0.6	36
353	Hoehn and Yahr Staging Scale. , 2010, , 23-25.		13
354	Most of the Quality of Life in Essential Tremor Questionnaire (QUEST) psychometric properties resulted in satisfactory values. Journal of Clinical Epidemiology, 2010, 63, 767-773.	5.0	39
355	What contributes to driving ability in Parkinson's disease. Disability and Rehabilitation, 2010, 32, 374-378.	1.8	23
356	International study on the psychometric attributes of the Non-Motor Symptoms Scale in Parkinson disease. Neurology, 2009, 73, 1584-1591.	1.1	213
357	Prevalence of dementia and major dementia subtypes in Spanish populations: A reanalysis of dementia prevalence surveys, 1990-2008. BMC Neurology, 2009, 9, 55.	1.8	115
358	Adherence to antiparkinson medication in a multicenter European study. Movement Disorders, 2009, 24, 826-832.	3.9	146
359	The clinical impression of severity index for Parkinson's disease: International validation study. Movement Disorders, 2009, 24, 211-217.	3.9	56
360	Psychometric attributes of the Hospital Anxiety and Depression Scale in Parkinson's disease. Movement Disorders, 2009, 24, 519-525.	3.9	68

#	ARTICLE	IF	CITATIONS
361	Rasch analysis of the hospital anxiety and depression scale in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 526-532.	3.9	29
362	Intrajejunal levodopa infusion in Parkinson's disease: A pilot multicenter study of effects on nonmotor symptoms and quality of life. <i>Movement Disorders</i> , 2009, 24, 1468-1474.	3.9	233
363	Cross-Cultural Validation of the Scales for Outcomes in Parkinson's Disease-Psychosocial Questionnaire (SCOPA-PS) in Four Latin American Countries. <i>Value in Health</i> , 2009, 12, 385-391.	0.3	10
364	PND44 EVALUATION OF THE IMPACT OF PARKINSON'S DISEASE SYMPTOMS ON HEALTH-RELATED QUALITY OF LIFE. PD-QOL STUDY. <i>Value in Health</i> , 2009, 12, A374.	0.3	0
365	P2.149 Efficacy of apomorphine infusion on mood and depression aspects of non-motor symptoms in advanced Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S130.	2.2	5
366	Systematic review of the effect of dopamine receptor agonists on patient health-related quality of life. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S58-S64.	2.2	16
367	Assessment tools for non-motor symptoms of Parkinson's disease. , 2009, , 47-58.		3
368	Non-motor symptoms and health-related quality of life. , 2009, , 309-320.		2
369	Psychometric attributes of the SCOPA-COG Brazilian version. <i>Movement Disorders</i> , 2008, 23, 81-87.	3.9	30
370	Validation of the "QUICK" questionnaire: A tool for diagnosis of "wearing-off" in patients with Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 830-836.	3.9	40
371	Burden, perceived health status, and mood among caregivers of Parkinson's disease patients. <i>Movement Disorders</i> , 2008, 23, 1673-1680.	3.9	166
372	SCOPA-sleep and PDSS: Two scales for assessment of sleep disorder in Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 1681-1688.	3.9	80
373	Longitudinal psychometric attributes, responsiveness, and importance of change: An approach using the SCOPA-Psychosocial questionnaire. <i>Movement Disorders</i> , 2008, 23, 1516-1523.	3.9	17
374	Apathy and anhedonia rating scales in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2008, 23, 2004-2014.	3.9	285
375	Anxiety rating scales in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2008, 23, 2015-2025.	3.9	208
376	Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. <i>Movement Disorders</i> , 2008, 23, 2129-2170.	3.9	4,796
377	Quantitation of non-motor symptoms in Parkinson's disease. <i>European Journal of Neurology</i> , 2008, 15, 2-8.	3.3	154
378	Specific patient-reported outcome measures for Parkinson's disease: analysis and applications. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2008, 8, 401-418.	1.4	14

#	ARTICLE	IF	CITATIONS
379	Anxiety and depression: Main determinants of health-related quality of life in Brazilian patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 102-108.	2.2	96
380	Surgery and Risk of Sporadic Creutzfeldt-Jakob Disease in Denmark and Sweden: Registry-Based Case-Control Studies. <i>Neuroepidemiology</i> , 2008, 31, 229-240.	2.3	56
381	Impact of fatigue in multiple sclerosis: the Fatigue Impact Scale for Daily Use (D-FIS). <i>Multiple Sclerosis Journal</i> , 2007, 13, 645-651.	3.0	48
382	The Patient Card Questionnaire to Identify Wearing-off in Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2007, 30, 266-275.	0.7	24
383	1.014 Non-motor symptoms in akinesia dominant versus other phenotypes in Parkinson's disease (PD): Results from the international PD non-motor symptoms scale study. <i>Parkinsonism and Related Disorders</i> , 2007, 13, S31.	2.2	1
384	1.126 Non-motor symptoms in akinesia dominant versus other phenotypes in Parkinson's disease (PD): Results from the international PD non-motor symptoms scale study. <i>Parkinsonism and Related Disorders</i> , 2007, 13, S40.	2.2	0
385	1.144 Changes in sexual interest and function in patients with Parkinson's disease: Focus on hypersexuality. <i>Parkinsonism and Related Disorders</i> , 2007, 13, S44-S45.	2.2	1
386	1.152 Dribbling of saliva in Parkinson's disease: Clinical correlations. <i>Parkinsonism and Related Disorders</i> , 2007, 13, S47.	2.2	0
387	2.003 Clinimetrics. <i>Parkinsonism and Related Disorders</i> , 2007, 13, S87.	2.2	0
388	2.262 Adherence to antiparkinson medication in a multi-centre European study.. <i>Parkinsonism and Related Disorders</i> , 2007, 13, S115.	2.2	0
389	3.420 Differential effect of the Parkinson's disease non-motor symptoms on patients' health-related quality of life. <i>Parkinsonism and Related Disorders</i> , 2007, 13, S185.	2.2	0
390	3.508 SCOPA-COG Brazilian Version: psychometric attributes. <i>Parkinsonism and Related Disorders</i> , 2007, 13, S189.	2.2	0
391	Scales to measure parkinsonism. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2007, 83, 289-327.	1.8	13
392	Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. <i>Movement Disorders</i> , 2007, 22, 41-47.	3.9	1,097
393	Independent validation of SCOPA's psychosocial and metric properties of the PDQ-39 Brazilian version. <i>Movement Disorders</i> , 2007, 22, 91-98.	3.9	54
394	Caregiver burden in Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 924-931.	3.9	208
395	Effect of medical and surgical interventions on health-related quality of life in Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 757-765.	3.9	75
396	Determinants of quality of life in Brazilian patients with Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 1408-1415.	3.9	80

#	ARTICLE	IF	CITATIONS
397	Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; Study using nonmotor symptoms questionnaire in 545 patients. <i>Movement Disorders</i> , 2007, 22, 1623-1629.	3.9	461
398	The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study. <i>Movement Disorders</i> , 2007, 22, 1901-1911.	3.9	838
399	Prospective comparative study on cost-effectiveness of subthalamic stimulation and best medical treatment in advanced Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 2183-2191.	3.9	81
400	Two questionnaires for Parkinson's disease: are the PDQ-39 and PDQL equivalent?. <i>Quality of Life Research</i> , 2007, 16, 1221-1230.	3.1	26
401	I.P2 Prevalence of non motor symptoms in Parkinson's Disease: An international survey using NMSQuest in 525 patients. <i>Parkinsonism and Related Disorders</i> , 2006, 12, 21.	2.2	2
402	The range and nature of sleep dysfunction in untreated Parkinson's disease (PD). A comparative controlled clinical study using the Parkinson's disease sleep scale and selective polysomnography. <i>Journal of the Neurological Sciences</i> , 2006, 248, 158-162.	0.6	99
403	Longitudinal Metric Properties of Disability Rating Scales for Parkinson's Disease. <i>Value in Health</i> , 2006, 9, 386-393.	0.3	45
404	Impact of Fatigue in Parkinson's Disease: The Fatigue Impact Scale for Daily Use (D-FIS). <i>Quality of Life Research</i> , 2006, 15, 597-606.	3.1	71
405	Global versus factor-related impression of severity in Parkinson's disease: A new clinimetric index (CISI-PD). <i>Movement Disorders</i> , 2006, 21, 208-214.	3.9	69
406	International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest study. <i>Movement Disorders</i> , 2006, 21, 916-923.	3.9	865
407	Metric attributes of the unified Parkinson's disease rating scale 3.0 battery: Part I, feasibility, scaling assumptions, reliability, and precision. <i>Movement Disorders</i> , 2006, 21, 1182-1188.	3.9	49
408	Metric attributes of the unified Parkinson's disease rating scale 3.0 battery: Part II, construct and content validity. <i>Movement Disorders</i> , 2006, 21, 1892-1898.	3.9	28
409	Non-motor symptoms in Parkinson's disease: an underdiagnosed problem. <i>Aging Health</i> , 2006, 2, 967-982.	0.3	19
410	The non-motor symptom complex of Parkinson's disease: A comprehensive assessment is essential. <i>Current Neurology and Neuroscience Reports</i> , 2005, 5, 275-283.	4.2	203
411	Quality of life of caregivers in Parkinson's disease. <i>Quality of Life Research</i> , 2005, 14, 463-472.	3.1	122
412	Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia, and Canada. <i>Neurology</i> , 2005, 64, 1586-1591.	1.1	306
413	The SCOPA-Motor Scale for assessment of Parkinson's disease is a consistent and valid measure. <i>Journal of Clinical Epidemiology</i> , 2005, 58, 674-679.	5.0	82
414	Psychometric characteristics of the Parkinson's disease questionnaire (PDQ-39) Ecuadorian version. <i>Parkinsonism and Related Disorders</i> , 2005, 11, 297-304.	2.2	23

#	ARTICLE	IF	CITATIONS
415	A short scale for the assessment of motor impairments and disabilities in Parkinson's disease: the SPES/SCOPA. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2004, 75, 388-395.	1.9	178
416	Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies. <i>Brain</i> , 2004, 127, 2348-2359.	7.6	244
417	Guidelines for the diagnosis and management of neurological complications of HIV infection. <i>European Journal of Neurology</i> , 2004, 11, 297-304.	3.3	97
418	Health-related quality of life evaluation by proxy in Parkinson's disease: Approach using PDQ-8 and EuroQoL-5D. <i>Movement Disorders</i> , 2004, 19, 312-318.	3.9	52
419	Parkinson's disease sleep scale: Validation study of a Spanish version. <i>Movement Disorders</i> , 2004, 19, 1226-1232.	3.9	44
420	Clinical Gait and Balance Scales for Parkinson's Disease. <i>Journal of the Neurological Sciences</i> , 2004, 221, 125.	0.6	3
421	Validation and cross-cultural adjustment of PDQL-questionnaire, Spanish version (Ecuador) (PDQL-EV). <i>Parkinsonism and Related Disorders</i> , 2004, 10, 433-437.	2.2	17
422	Clinical assessment of nocturnal disability in Parkinson's disease. <i>Neurology</i> , 2004, 63, S17-20.	1.1	36
423	Patients', doctors', and caregivers' assessment of disability using the UPDRS-ADL section: Are these ratings interchangeable?. <i>Movement Disorders</i> , 2003, 18, 985-992.	3.9	47
424	A short psychosocial questionnaire for patients with Parkinson's disease. <i>Journal of Clinical Epidemiology</i> , 2003, 56, 61-67.	5.0	97
425	Bilateral subthalamic nucleus stimulation and quality of life in advanced Parkinson's disease. <i>Movement Disorders</i> , 2002, 17, 372-377.	3.9	148
426	Efficacy and Safety of Metamizol vs. Acetylsalicylic Acid in Patients With Moderate Episodic Tension-Type Headache: A Randomized, Double-Blind, Placebo- and Active-Controlled, Multicentre Study. <i>Cephalgia</i> , 2001, 21, 604-610.	3.9	65
427	Health-related quality of life in Parkinson's disease: outcomes of the therapeutic interventions. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2001, 1, 99-108.	1.4	7
428	Pallidotomy and quality of life in patients with parkinson's disease: An early study. <i>Movement Disorders</i> , 2000, 15, 65-70.	3.9	56
429	Parkinson's disease: quantification of disability based on the Unified Parkinson's Disease Rating Scale. <i>Neurología</i> , 2000, 15, 382-7.	0.7	16
430	Drug-induced tardive syndromes. <i>Parkinsonism and Related Disorders</i> , 1999, 5, 59-65.	2.2	43
431	Conversion to controlled-release levodopa/carbidopa treatment and quality of life as measured by the Nottingham Health Profile. The STAR Study Group. <i>Neurología</i> , 1999, 14, 338-43.	0.7	8
432	An introduction to the concept of "quality of life in Parkinson's disease". <i>Journal of Neurology</i> , 1998, 245, S2-S6.	3.6	151

#	ARTICLE	IF	CITATIONS
433	Quality of life in patients with Parkinson's disease who transfer from standard levodopa to Sinemet CR: the STAR study. <i>Journal of Neurology</i> , 1998, 245, S31-S33.	3.6	15
434	Quality of life in Parkinson's disease: validation study of the PDQ-39 Spanish version. <i>Journal of Neurology</i> , 1998, 245, S34-S38.	3.6	94
435	Extending levodopa action. <i>Neurology</i> , 1998, 50, S27-32; discussion S44-8.	1.1	38
436	Infections of the Nervous System Caused by Varicella-Zoster Virus: A Review. <i>Intervirology</i> , 1997, 40, 72-84.	2.8	79
437	A New Clinical Tool for Gait Evaluation in Parkinson's Disease. <i>Clinical Neuropharmacology</i> , 1997, 20, 183-194.	0.7	61
438	Evaluation of the Short Parkinson's Evaluation Scale. <i>Clinical Neuropharmacology</i> , 1997, 20, 322-337.	0.7	51
439	Evaluation of the Short Parkinson's Evaluation Scale: a new friendly scale for the evaluation of Parkinson's disease in clinical drug trials. <i>Clinical Neuropharmacology</i> , 1997, 20, 322-37.	0.7	12
440	Dual detection of antibody to both herpes simplex and varicella-zoster viruses in cerebrospinal fluid: Cross reactivity or dual infection?. <i>Journal of Neurology</i> , 1996, 243, 618-619.	3.6	1
441	Intermediate scale for assessment of Parkinson's disease. Characteristics and structure. <i>Parkinsonism and Related Disorders</i> , 1995, 1, 97-102.	2.2	25
442	Detection of varicella-zoster virus-specific DNA sequences in cerebrospinal fluid from patients with acute aseptic meningitis and no cutaneous lesions. <i>Journal of Medical Virology</i> , 1994, 43, 331-335.	5.0	136
443	Unified Parkinson's disease rating scale characteristics and structure. <i>Movement Disorders</i> , 1994, 9, 76-83.	3.9	658
444	Comparative sensitivity of different criteria for interpreting antibody tests in cerebrospinal fluid from patients with acute viral meningitis. <i>Serodiagnosis and Immunotherapy in Infectious Disease</i> , 1990, 4, 193-199.	0.2	9
445	Myopathy with nemaline structures associated with HIV infection. <i>Journal of Neurology</i> , 1990, 237, 64-65.	3.6	26
446	Subclass Distribution of the Serum and Intrathecal IgG Antibody Response in Varicella-Zoster Virus Infections. <i>Journal of Infectious Diseases</i> , 1990, 162, 621-626.	4.0	19
447	Aseptic Meningitis Due to Varicella-Zoster Virus: Serum Antibody Levels and Local Synthesis of Specific IgG, IgM, and IgA. <i>Journal of Infectious Diseases</i> , 1987, 155, 959-967.	4.0	51
448	Intrathecal synthesis of IgG antibodies to varicella-zoster virus in two cases of acute aseptic meningitis syndrome with no cutaneous lesions. <i>Journal of Medical Virology</i> , 1985, 16, 201-209.	5.0	46
449	Familial writer's cramp.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1985, 48, 487-487.	1.9	9
450	CLUSTERS OF SHINGLES. <i>Lancet, The</i> , 1985, 326, 1433-1434.	13.7	2